2022 World Conference on Lung Cancer (ePosters)-EP08.01-055. Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer

EP08.01-055. Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer

Back to course

Pdf Summary

This study focuses on the utilization of tumor mutational profiling to identify the response to immunotherapy in non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors have shown clinical benefit in NSCLC, but there is a need for biomarkers to predict immunotherapy response. The researchers explored the genomic profiling of NSCLC with immunotherapy to help guide prediction of response.<br /><br />The study found that the most relevant mutational signature in the response group was signature 4, which is associated with direct exposure to tobacco mutagens. The co-mutation of SSC5D and TTN, DSPP and RBMXL3 may be helpful in identifying the response to immunotherapy and personalized treatment in NSCLC. TP53, KMT2D, and KMT2C were the frequently mutated genes detected in more than 20% of cases, and CA transversions associated with smoking were the dominant base substitutions.<br /><br />The most relevant mutational signature in the PR and SD groups was signature 4, while in the PD group it was signature 13 (APOBEC Cytidine Deaminase). The co-occurrence mutations were different in patients with PR, SD, and PD outcomes. Tumors with HLA LOH had higher levels of tumor mutational burden (TMB).<br /><br />The study included 65 NSCLC patients and used baseline tumor specimens. Whole-exome sequencing and targeted sequencing were performed, and immunotherapy response was assessed. Statistical analysis was conducted to determine differences in signatures between the HLA intact and LOH groups.<br /><br />In conclusion, the study suggests that tumor mutational profiling can be used to identify the response to immunotherapy in NSCLC. Mutational signatures and co-mutations may serve as biomarkers for predicting response and guiding personalized treatment. Nonetheless, further research is still needed in this area.

Asset Subtitle

Wenbin Li

Meta Tag

Speaker Wenbin Li

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

tumor mutational profiling

immunotherapy

non-small cell lung cancer

biomarkers

mutational signature

co-mutation

personalized treatment

HLA LOH

tumor mutational burden

targeted sequencing